LEGEND rule-out strategy reduces length of stay and testing in suspected ACS patients across four Australian emergency departmentsA new strategy safely shortens hospital stays for suspected heart attacks

This study employed a stepped-wedge cluster randomized controlled trial design to evaluate the impact of the LEGEND rule-out strategy on patient outcomes and resource utilization in the setting of suspected acute coronary syndrome. The investigation was conducted across four emergency departments in Australia, enrolling a total of 9,944 adult patients presenting with suspected acute coronary syndrome. The intervention arm utilized the LEGEND rule-out strategy, which integrates high-sensitivity cardiac troponin assay concentrations with shared decision making protocols. The comparator arm received standard care as per local protocols. The study followed participants for 30 days to assess short-term clinical events.

The primary outcome of interest was the length of hospital stay. Results indicated that the mean length of stay was 3.6 hours shorter in the intervention arm compared to the standard care arm. The 95% confidence interval for this reduction ranged from 2.5 to 4.6 hours, with a p-value indicating statistical significance. This reduction in length of stay suggests a potential for improved patient throughput and resource management within the emergency department setting.

Several secondary outcomes were assessed to evaluate the broader impact of the intervention. The proportion of patients discharged from the hospital within 4 hours increased by 22.9% in the intervention group, with a 95% confidence interval of 19.5% to 26.3%. Concurrently, the utilization of cardiac testing decreased by 7.8%, with a 95% confidence interval of 4.6% to 11.1%. These shifts indicate that the strategy effectively streamlined diagnostic pathways, allowing for earlier discharge and reduced reliance on extensive testing for patients who could be safely ruled out.

Regarding safety and tolerability, the study reported no differences in representations, index events, or 30-day events between the intervention and standard care arms. The intervention was deemed to safely rule out acute myocardial infarction without introducing new risks. Specific data on adverse events, serious adverse events, discontinuations, or detailed tolerability metrics were not reported in the provided evidence. The absence of observed differences in major clinical events supports the safety profile of the strategy in this population.

When compared to prior landmark studies in the therapeutic area of acute coronary syndrome management, this trial provides contemporary evidence supporting the integration of high-sensitivity troponin assays with shared decision making. Previous studies have often focused on the diagnostic accuracy of troponin assays; this study extends that knowledge by demonstrating operational benefits such as reduced length of stay and increased early discharge. However, the specific comparison to prior landmark studies regarding the magnitude of these operational improvements was not detailed in the provided data.

Methodological limitations inherent to the study design and reporting were noted. The study phase and publication type were not reported. Additionally, specific absolute numbers for outcomes were not reported, which limits the ability to calculate absolute risk reductions or event rates directly from the provided text. The lack of reported funding sources or conflicts of interest also represents a limitation in assessing potential bias, although the study design itself (stepped-wedge cluster RCT) generally mitigates some selection biases associated with parallel-group trials.

The clinical implications of these findings suggest that emergency departments considering the adoption of the LEGEND rule-out strategy may achieve significant reductions in length of stay and resource utilization. The strategy appears to facilitate earlier discharge for low-risk patients without compromising safety. Clinicians should consider integrating high-sensitivity cardiac troponin data with shared decision making to optimize patient flow. However, the generalizability of these results to other healthcare systems or populations remains to be fully established.

Several questions remain unanswered based on the current evidence. The long-term outcomes beyond 30 days were not assessed. The specific protocols for shared decision making within the LEGEND strategy were not detailed in the provided text. Furthermore, the impact of the intervention on patient satisfaction or health-related quality of life was not reported. Future research should aim to address these gaps and confirm the sustainability of these operational improvements in diverse clinical settings.